Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1 '-hydroxylation

Aims To characterize the effect of an oral contraceptive (OC) containing et hinylestradiol and gestodene on the activity of CYP3A4 in vivo as measured by the 1'-hydroxylation of midazolam. Methods In this randomised, double-blind, cross-over trial nine healthy fem ale subjects received either a combined OC (30 mu g ethinylestradiol and 75 mu g gestodene) or placebo once daily for 10 days. On day 10, a single 7.5 mg dose of midazolam was given orally. Plasma concentrations of midazolam and 1'-hydroxymidazolam were determined up to 24 h and the effects of midaz olam were measured with three psychomotor tests up to 8 h. Results The combined OC increased the mean AUC of midazolam by 21% (95% CI 2% to 40%; P = 0.03) and decreased that of 1'-hydroxymidazolam by 25% (95% CI 10% to 41%; P = 0.01), compared with placebo. The metabolic ratio (AUC o f 1'-hydroxymidazolam/AUC of midazolam) was 36% smaller (95% CI 19% to 53%; P = 0.01) in the OC phase than in the placebo phase. There were no signifi cant differences in the C-max, t(max), t(1/2) or effects of midazolam betwe en the phases. Conclusions A combined OC preparation caused a modest reduction in the acti vity of CYP3A4, as measured by the 1'-hydroxylation of midazolam, and sligh tly increased the AUC of oral midazolam. This study suggests that, at the d oses used, ethinylestradiol and gestodene have a relatively small effect on CYP3A4 activity in vivo.